Celator Pharms Company Profile
✉ Email this page to a colleague
What is the competitive landscape for CELATOR PHARMS, and when can generic versions of CELATOR PHARMS drugs launch?
CELATOR PHARMS has one approved drug.
There are nine US patents protecting CELATOR PHARMS drugs.
There are one hundred and twenty-seven patent family members on CELATOR PHARMS drugs in twenty-six countries and thirty-six supplementary protection certificates in sixteen countries.
Summary for Celator Pharms
| International Patents: | 127 |
| US Patents: | 9 |
| Tradenames: | 1 |
| Ingredients: | 1 |
| NDAs: | 1 |
Drugs and US Patents for Celator Pharms
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Celator Pharms | VYXEOS | cytarabine; daunorubicin | POWDER;INTRAVENOUS | 209401-001 | Aug 3, 2017 | RX | Yes | Yes | ⤷ Try a Trial | ⤷ Try a Trial | |||||
| Celator Pharms | VYXEOS | cytarabine; daunorubicin | POWDER;INTRAVENOUS | 209401-001 | Aug 3, 2017 | RX | Yes | Yes | 8,431,806 | ⤷ Try a Trial | Y | ⤷ Try a Trial | |||
| Celator Pharms | VYXEOS | cytarabine; daunorubicin | POWDER;INTRAVENOUS | 209401-001 | Aug 3, 2017 | RX | Yes | Yes | 7,850,990 | ⤷ Try a Trial | Y | ⤷ Try a Trial | |||
| Celator Pharms | VYXEOS | cytarabine; daunorubicin | POWDER;INTRAVENOUS | 209401-001 | Aug 3, 2017 | RX | Yes | Yes | 10,028,912 | ⤷ Try a Trial | Y | ⤷ Try a Trial | |||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |
International Patents for Celator Pharms Drugs
| Country | Patent Number | Estimated Expiration |
|---|---|---|
| Australia | 2008216083 | ⤷ Try a Trial |
| Poland | 3300601 | ⤷ Try a Trial |
| Australia | 2002340669 | ⤷ Try a Trial |
| Slovenia | 2768484 | ⤷ Try a Trial |
| >Country | >Patent Number | >Estimated Expiration |
Supplementary Protection Certificates for Celator Pharms Drugs
| Patent Number | Supplementary Protection Certificate | SPC Country | SPC Expiration | SPC Description |
|---|---|---|---|---|
| 3300601 | C20220023 00369 | Estonia | ⤷ Try a Trial | PRODUCT NAME: DAUNORUBITSIIN / TSUETARABIIN;REG NO/DATE: EU/1/18/1308; 27.08.2018 |
| 1744764 | C01744764/01 | Switzerland | ⤷ Try a Trial | PRODUCT NAME: DAUNORUBICIN UND CYTARABIN; REGISTRATION NO/DATE: SWISSMEDIC-ZULASSUNG 68014 17.02.2022 |
| 2768484 | 132019000000144 | Italy | ⤷ Try a Trial | PRODUCT NAME: DAUNORUBICINA E CITARABINA(VYXEOS); AUTHORISATION NUMBER(S) AND DATE(S): EU/1/18/1308, 20180827 |
| 1744764 | 18C1047 | France | ⤷ Try a Trial | PRODUCT NAME: DAUNORUBICINE + CYTARABINE; REGISTRATION NO/DATE: EU/1/18/1308 20180827 |
| >Patent Number | >Supplementary Protection Certificate | >SPC Country | >SPC Expiration | >SPC Description |
Similar Applicant Names
Applicants may be listed under multiple names.
Here is a list of applicants with similar names.
Here is a list of applicants with similar names.
